Treglia Giorgio, Annunziata Salvatore, Pizzuto Daniele A, Giovanella Luca, Prior John O, Ceriani Luca
Clinic of Nuclear Medicine and Molecular Imaging, Imaging Institute of Southern Switzerland, CH-6500 Bellinzona, Switzerland.
Health Technology Assessment Unit, Ente Ospedaliero Cantonale, CH-6500 Bellinzona, Switzerland.
Cancers (Basel). 2019 May 23;11(5):710. doi: 10.3390/cancers11050710.
: The use of radiolabeled prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) for biochemical recurrent prostate cancer (BRPCa) is increasing worldwide. Recently, F-labeled PSMA agents have become available. We performed a systematic review and meta-analysis regarding the detection rate (DR) of F-labeled PSMA PET/CT in BRPCa to provide evidence-based data in this setting. : A comprehensive literature search of PubMed/MEDLINE, EMBASE, and Cochrane Library databases through 23 April 2019 was performed. Pooled DR was calculated on a per-patient basis, with pooled proportion and 95% confidence interval (95% CI). Furthermore, pooled DR of F-PSMA PET/CT using different cut-off values of prostate-specific antigen (PSA) was obtained. : Six articles (645 patients) were included in the meta-analysis. The pooled DR of F-labeled PSMA PET/CT in BRPCa was 81% (95% CI: 71-88%). The pooled DR was 86% for PSA ≥ 0.5 ng/mL (95% CI: 78-93%) and 49% for PSA < 0.5 ng/mL (95% CI: 23-74%). Statistical heterogeneity was found. : F-labeled PSMA PET/CT demonstrated a good DR in BRPCa. DR of F-labeled PSMA PET/CT is related to PSA values with significant lower DR in patients with PSA < 0.5 ng/mL. Prospective multicentric trials are needed to confirm these findings.
放射性标记的前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描（PSMA PET/CT）在生化复发前列腺癌（BRPCa）中的应用在全球范围内日益增加。最近，氟标记的PSMA制剂已可获得。我们进行了一项关于氟标记的PSMA PET/CT在BRPCa中的检测率（DR）的系统评价和荟萃分析，以提供该情况下基于证据的数据。：通过检索截至2019年4月23日的PubMed/MEDLINE、EMBASE和Cochrane图书馆数据库进行了全面的文献搜索。以每位患者为基础计算合并检测率，并计算合并比例和95%置信区间（95%CI）。此外，还获得了使用不同前列腺特异性抗原（PSA）临界值的氟-PSMA PET/CT的合并检测率。：六项研究（645例患者）纳入荟萃分析。氟标记的PSMA PET/CT在BRPCa中的合并检测率为81%（95%CI：71-88%）。PSA≥0.5 ng/mL时合并检测率为86%（95%CI：78-93%），PSA<0.5 ng/mL时为49%（95%CI：23-74%）。发现存在统计学异质性。：氟标记的PSMA PET/CT在BRPCa中显示出良好的检测率。氟标记的PSMA PET/CT的检测率与PSA值相关，PSA<0.5 ng/mL的患者检测率显著较低。需要进行前瞻性多中心试验来证实这些发现。
Zotero 插件
